Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis

Results from the BONE study

Robert R. Recker, R. S. Weinstein, C. H. Chesnut, R. C. Schimmer, P. Mahoney, C. Hughes, B. Bonvoisin, P. J. Meunier

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

The bisphosphonate ibandronate, administered either daily or intermittently with an extended between-dose interval of > 2 months, has been shown to reduce significantly the incidence of vertebral fractures, to increase bone mineral density and to reduce levels of biochemical markers of bone turnover in a phase III randomized study in women with postmenopausal osteoporosis (PMO). Bone histomorphometry was performed on a subgroup of women participating in this study in order to assess bone quality and architecture. The patients were randomized to receive one of the following: placebo, continuous oral daily ibandronate (2.5 mg/day) or intermittent oral ibandronate (20 mg every other day for 12 doses every 3 months). Out of the overall study population of 2,946 patients, 110 were randomly assigned to undergo transiliac bone biopsy at either month 22 or month 34 of treatment. The primary safety endpoint was osteoid thickness in trabecular bone, which was measured to exclude treatment-induced bone mineralization defects. Secondary safety endpoints assessed bone volume, bone turnover and micro-architecture. The primary efficacy endpoint was bone mineralizing surface. In all bone biopsy cores, newly formed trabecular bone retained its structure without any signs of woven bone. Marrow fibrosis and signs of cellular toxicity were not observed. Quantitative assessment demonstrated no impairment in mineralization of bone matrix: osteoid thickness tended to be similar or slightly lower in the ibandronate groups versus the placebo group. All secondary safety variables and the bone efficacy parameter were consistent with the production of normal-quality, newly formed bone and a modest reduction in bone turnover with both ibandronate regimens relative to placebo. Long-term treatment with oral ibandronate, even when administered with an extended between-dose interval of > 2 months, produces normal-quality, newly formed bone in women with PMO.

Original languageEnglish
Pages (from-to)231-237
Number of pages7
JournalOsteoporosis International
Volume15
Issue number3
DOIs
StatePublished - Mar 2004

Fingerprint

Postmenopausal Osteoporosis
Bone and Bones
Bone Remodeling
Placebos
Safety
ibandronic acid
Biopsy
Physiologic Calcification
Bone Matrix
Diphosphonates
Bone Density
Fibrosis
Therapeutics
Biomarkers
Bone Marrow

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis : Results from the BONE study. / Recker, Robert R.; Weinstein, R. S.; Chesnut, C. H.; Schimmer, R. C.; Mahoney, P.; Hughes, C.; Bonvoisin, B.; Meunier, P. J.

In: Osteoporosis International, Vol. 15, No. 3, 03.2004, p. 231-237.

Research output: Contribution to journalArticle

Recker, Robert R. ; Weinstein, R. S. ; Chesnut, C. H. ; Schimmer, R. C. ; Mahoney, P. ; Hughes, C. ; Bonvoisin, B. ; Meunier, P. J. / Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis : Results from the BONE study. In: Osteoporosis International. 2004 ; Vol. 15, No. 3. pp. 231-237.
@article{725068f777554b829c77a64c6f15bcc0,
title = "Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: Results from the BONE study",
abstract = "The bisphosphonate ibandronate, administered either daily or intermittently with an extended between-dose interval of > 2 months, has been shown to reduce significantly the incidence of vertebral fractures, to increase bone mineral density and to reduce levels of biochemical markers of bone turnover in a phase III randomized study in women with postmenopausal osteoporosis (PMO). Bone histomorphometry was performed on a subgroup of women participating in this study in order to assess bone quality and architecture. The patients were randomized to receive one of the following: placebo, continuous oral daily ibandronate (2.5 mg/day) or intermittent oral ibandronate (20 mg every other day for 12 doses every 3 months). Out of the overall study population of 2,946 patients, 110 were randomly assigned to undergo transiliac bone biopsy at either month 22 or month 34 of treatment. The primary safety endpoint was osteoid thickness in trabecular bone, which was measured to exclude treatment-induced bone mineralization defects. Secondary safety endpoints assessed bone volume, bone turnover and micro-architecture. The primary efficacy endpoint was bone mineralizing surface. In all bone biopsy cores, newly formed trabecular bone retained its structure without any signs of woven bone. Marrow fibrosis and signs of cellular toxicity were not observed. Quantitative assessment demonstrated no impairment in mineralization of bone matrix: osteoid thickness tended to be similar or slightly lower in the ibandronate groups versus the placebo group. All secondary safety variables and the bone efficacy parameter were consistent with the production of normal-quality, newly formed bone and a modest reduction in bone turnover with both ibandronate regimens relative to placebo. Long-term treatment with oral ibandronate, even when administered with an extended between-dose interval of > 2 months, produces normal-quality, newly formed bone in women with PMO.",
author = "Recker, {Robert R.} and Weinstein, {R. S.} and Chesnut, {C. H.} and Schimmer, {R. C.} and P. Mahoney and C. Hughes and B. Bonvoisin and Meunier, {P. J.}",
year = "2004",
month = "3",
doi = "10.1007/s00198-003-1530-0",
language = "English",
volume = "15",
pages = "231--237",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "3",

}

TY - JOUR

T1 - Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis

T2 - Results from the BONE study

AU - Recker, Robert R.

AU - Weinstein, R. S.

AU - Chesnut, C. H.

AU - Schimmer, R. C.

AU - Mahoney, P.

AU - Hughes, C.

AU - Bonvoisin, B.

AU - Meunier, P. J.

PY - 2004/3

Y1 - 2004/3

N2 - The bisphosphonate ibandronate, administered either daily or intermittently with an extended between-dose interval of > 2 months, has been shown to reduce significantly the incidence of vertebral fractures, to increase bone mineral density and to reduce levels of biochemical markers of bone turnover in a phase III randomized study in women with postmenopausal osteoporosis (PMO). Bone histomorphometry was performed on a subgroup of women participating in this study in order to assess bone quality and architecture. The patients were randomized to receive one of the following: placebo, continuous oral daily ibandronate (2.5 mg/day) or intermittent oral ibandronate (20 mg every other day for 12 doses every 3 months). Out of the overall study population of 2,946 patients, 110 were randomly assigned to undergo transiliac bone biopsy at either month 22 or month 34 of treatment. The primary safety endpoint was osteoid thickness in trabecular bone, which was measured to exclude treatment-induced bone mineralization defects. Secondary safety endpoints assessed bone volume, bone turnover and micro-architecture. The primary efficacy endpoint was bone mineralizing surface. In all bone biopsy cores, newly formed trabecular bone retained its structure without any signs of woven bone. Marrow fibrosis and signs of cellular toxicity were not observed. Quantitative assessment demonstrated no impairment in mineralization of bone matrix: osteoid thickness tended to be similar or slightly lower in the ibandronate groups versus the placebo group. All secondary safety variables and the bone efficacy parameter were consistent with the production of normal-quality, newly formed bone and a modest reduction in bone turnover with both ibandronate regimens relative to placebo. Long-term treatment with oral ibandronate, even when administered with an extended between-dose interval of > 2 months, produces normal-quality, newly formed bone in women with PMO.

AB - The bisphosphonate ibandronate, administered either daily or intermittently with an extended between-dose interval of > 2 months, has been shown to reduce significantly the incidence of vertebral fractures, to increase bone mineral density and to reduce levels of biochemical markers of bone turnover in a phase III randomized study in women with postmenopausal osteoporosis (PMO). Bone histomorphometry was performed on a subgroup of women participating in this study in order to assess bone quality and architecture. The patients were randomized to receive one of the following: placebo, continuous oral daily ibandronate (2.5 mg/day) or intermittent oral ibandronate (20 mg every other day for 12 doses every 3 months). Out of the overall study population of 2,946 patients, 110 were randomly assigned to undergo transiliac bone biopsy at either month 22 or month 34 of treatment. The primary safety endpoint was osteoid thickness in trabecular bone, which was measured to exclude treatment-induced bone mineralization defects. Secondary safety endpoints assessed bone volume, bone turnover and micro-architecture. The primary efficacy endpoint was bone mineralizing surface. In all bone biopsy cores, newly formed trabecular bone retained its structure without any signs of woven bone. Marrow fibrosis and signs of cellular toxicity were not observed. Quantitative assessment demonstrated no impairment in mineralization of bone matrix: osteoid thickness tended to be similar or slightly lower in the ibandronate groups versus the placebo group. All secondary safety variables and the bone efficacy parameter were consistent with the production of normal-quality, newly formed bone and a modest reduction in bone turnover with both ibandronate regimens relative to placebo. Long-term treatment with oral ibandronate, even when administered with an extended between-dose interval of > 2 months, produces normal-quality, newly formed bone in women with PMO.

UR - http://www.scopus.com/inward/record.url?scp=1642371153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642371153&partnerID=8YFLogxK

U2 - 10.1007/s00198-003-1530-0

DO - 10.1007/s00198-003-1530-0

M3 - Article

VL - 15

SP - 231

EP - 237

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 3

ER -